Navigation Links
Rigel's R343 Did Not Meet Primary Endpoint in Asthma Study
Date:8/26/2013

SOUTH SAN FRANCISCO, Calif., Aug. 26, 2013 /PRNewswire/ -- Rigel Pharmaceuticals, Inc. (Nasdaq: RIGL) today announced that R343, an inhaled SYK inhibitor being evaluated as a potential therapeutic for patients with allergic asthma, did not meet the primary or secondary endpoints in a recently completed Phase 2 clinical study.  The primary endpoint was the change in pre-bronchodilator FEV1 (a measure of lung function) from baseline to dosing completion at Week 8, comparing active doses to placebo. R343 was shown to be relatively safe and well tolerated at both doses. In light of these overall findings, the company has decided not to pursue this indication with R343.

"This was not the result we expected based on the collection of data we had previously seen with R343 in this therapeutic area," said James M. Gower, chairman and chief executive officer of Rigel.  "Fortunately, we have a robust portfolio of clinical and preclinical research programs to focus on that includes Fostamatinib, R333 for discoid lupus erythematosus and R348 for dry eye.  We will be reviewing our portfolio and will discuss these plans in the near-term," he added.  

About Rigel (www.rigel.com)
Rigel Pharmaceuticals, Inc. is a clinical-stage drug development company that discovers and develops novel, small-molecule drugs for the treatment of inflammatory and autoimmune diseases, as well as muscle disorders.  Rigel's pioneering research focuses on intracellular signaling pathways and related targets that are critical to disease mechanisms. The company currently has five product candidates in clinical development: fostamatinib, an oral SYK for immune disorders; R333, a topical JAK/SYK inhibitor for discoid lupus, and R348, a topical JAK/SYK inhibitor for chronic dry eye 
'/>"/>

SOURCE Rigel Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2

Related medicine technology :

1. ARRY-502 Meets Primary And Key Secondary Endpoints In Asthma Study
2. TREATMENT OF PRIMARY LIVER CANCER: SARAH STUDY NOW AVAILABLE FOR ALL ELIGIBLE PATIENTS THROUGHOUT FRANCE
3. OxThera Strengthens Patent Portfolio for Orphan Disease - Primary Hyperoxaluria
4. Primary Efficacy and Safety Findings from Phase 3 Study of Janssens Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients
5. Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
6. Lilly Announces Enzastaurin Phase III Study Did Not Meet Primary Endpoint in Diffuse Large B-Cell Lymphoma
7. Carena Launches 24/7 Virtual Care Delivery Service for Hospital Systems and Primary Care Clinics
8. Top-line Data Show AcelRx Pharmaceuticals ARX-04 Achieves Primary Endpoint in Dose-Finding Phase 2 Clinical Trial
9. Idaho Primary Care Association Receives Cambia Health Foundation grant for "Idaho Patient-Centered Medical Home" development in Idaho Community Health Centers
10. Chipscreen Biosciences Announces Achievement of Primary Endpoint in Chidamide Registrational Trial in China
11. April is National Primary Immunodeficiency Awareness Month
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... LONDON , December 19, 2014 ... authentication services in the World announced the appointment of ... Anthony R. Vonsée, as Chief Channels and Partner Officer. ... Datanomic since 2004 through to its acquisition by Oracle ... Development Director at Geneva and ...
(Date:12/19/2014)... -- You,re visiting the dentist for what you think ... she says you need a root canal. Though it,s ... several questions and feel apprehensive about your upcoming procedure. ... to worry about. The Pennsylvania Dental Association (PDA) wants ... the public may have surrounding this common procedure that ...
(Date:12/19/2014)... , Dec. 19, 2014 Breckenridge Pharmaceutical, ... multi-product agreement with MSN Laboratories Pvt. Ltd. ( ... expect to commercialize several new ANDAs.  Under the terms ... the products exclusively to Breckenridge for the U.S. market, ... its label.  Breckenridge and MSN have agreed to develop ...
Breaking Medicine Technology:Aegate Appoints new CTO and Chief Channels & Partner Officer 2Aegate Appoints new CTO and Chief Channels & Partner Officer 3Aegate Appoints new CTO and Chief Channels & Partner Officer 4Root Canals Have Become More Routine 2Breckenridge Pharmaceutical signs Multi-Product Generic Agreement with MSN Laboratories Pvt. Ltd. 2
... 2 Cornerstone Therapeutics Inc. (Nasdaq: ... specialty pharmaceutical company focused on acquiring, developing and commercializing ... today announced that the Company has entered into a ... Inc, also known as The Cough Company ("The Cough ...
... ,  Aug. 2 K-V Pharmaceutical Company (NYSE: ... New York Stock Exchange ("NYSE") on July 27, 2010 ...  The NYSE informed the Company that its Class A Common ... closing price of a NYSE security of not less than ...
Cached Medicine Technology:Cornerstone Therapeutics Announces Collaboration with The Cough Company 2Cornerstone Therapeutics Announces Collaboration with The Cough Company 3Cornerstone Therapeutics Announces Collaboration with The Cough Company 4K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 2K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 3K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 4K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 5K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 6K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 7K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 8K-V Pharmaceutical Company Notified by New York Stock Exchange of Non-Compliance With Continued Listing Standards 9
(Date:12/21/2014)... (PRWEB) December 21, 2014 AlignLife of ... in need while at the same time helping people get ... a non-profit community-based organization committed to serving those persons in ... their needs to improve the quality of life. Dr. Michael ... an impact in the local community and he knew he ...
(Date:12/21/2014)... Aliso Viejo, California (PRWEB) December 21, 2014 ... Film Studios have announced a new intro plugin for ... users to animate pictures, videos, logos, and more with ... Studios. “We’ve given our users the tools needed to ... Studios' ProMotion allows Final Cut Pro X users to ...
(Date:12/20/2014)... 21, 2014 BambooIndustry.com is a professional ... . The business has recently shown its new engineered ... all its bamboo flooring models. , BambooIndustry.com’s customers come ... Asia and more. According to the CEO of the ... very fast in the past few years, and the ...
(Date:12/20/2014)... 20, 2014 Dress company LunaDress has recently ... announced its Christmas Sale, offering big discounts on all of ... has an idea to own a perfect wedding gown. If ... wedding dress, then come to LunaDress. Many different wedding dress ... Visit our website now and enjoy the current special offer, ...
(Date:12/20/2014)... 2014 The Doctor’s Office Urgent Care of ... part of a decade. They’ve treated over 40,000 patients ... healthcare alternative to the Paramus area. , ... additions to their staff of top-notch board certified physicians: Christine ... These new doctors will work tirelessly to carry ...
Breaking Medicine News(10 mins):Health News:AlignLife of Norton Shores Makes a Brighter Christmas for Kids in Muskegon 2Health News:Announcing a new plugin for Final Cut Pro X ProMotion from Pixel Film Studios. 2Health News:BammbooIndustry.com: Big Discounts On All Kinds Of Bamboo Flooring Collections 2Health News:2015 Collection of Wedding Dresses from LunaDress Online on Sale Now 2Health News:The Doctor's Office Urgent Care Adds 3 New Physicians to Their Growing Medical Team 2
... ... Texas. , ... 2010 -- Rosenheck and Co., Inc. is excited to announce our new website for 2010. ... products for Oklahoma and Texas . Thousands of seniors depend ...
... would block hormone that controls uterine contractions , ... shows promise in treating severe menstrual cramps, researchers say. ... 90 percent of women of child-bearing age and is ... women in their teens and 20s, according to a ...
... for early halt, expert says , TUESDAY, March 23 ... in clinical trials that are stopped early due to ... a comparison of 91 truncated trials with 424 comparable ... early -- in particular, smaller studies -- reported exaggerated ...
... March 23 A national poll released recently by Rasmussen Reports shows that 56 percent of Americans oppose a tax on soft drinks, strongly believing that ... ... ... ...
... , , ... ... ... ...
... agent that targets metastatic breast cancer to find if it ... cancer patients, whose disease has spread despite treatment, could be ... determine the efficacy of an investigational agent used to target ... one of the things we can offer patients is our ...
Cached Medicine News:Health News:Rosenheck and Co. Launches New Website Outlining Medicare Supplement Services for Oklahoma and Texas 2Health News:Menstrual Cramps May Be Helped by New Drug 2Health News:Abbreviated Trials Yield Misleading Results: Study 2Health News:National Poll Finds Americans Oppose Tax on Soft Drinks; Don't Believe it Will Go to Improve Public Health 2Health News:National Poll Finds Americans Oppose Tax on Soft Drinks; Don't Believe it Will Go to Improve Public Health 3Health News:National Poll Finds Americans Oppose Tax on Soft Drinks; Don't Believe it Will Go to Improve Public Health 4Health News:Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion 2Health News:Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion 3Health News:Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion 4Health News:Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion 5Health News:Bishops Encourage Vigilance that Health Care Legislation Protects Conscience, Does Not Fund Abortion 6
... to detect sequences of the following ... 2 and 3; influenza virus A ... A and B. Laboratories may ... tests., *Analyte Specific Reagents. ...
... molecular labs a more advanced alternative for ... MGB technology, combined with post-PCR dissociation melt ... provide molecular labs more powerful tools for ... or genetic mutations associated with disease, as ...
... NGEN-brand ASRs* are specifically designed for ... with two-color fluorescence detection systems. The ... the detection of mutations associated with ... as well as reagents for the ...
... offers reagents for the detection of ... the G1691A mutation on the Factor ... mutation on the Prothrombin gene. Laboratories ... homebrew tests.,, *Analyte Specific ...
Medicine Products: